Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2004

01-03-2004 | Review

The use of gene function to identify the rate-limiting steps controlling cell fate

Authors: Gwyn T. Williams, Farzin Farzaneh

Published in: Cancer Immunology, Immunotherapy | Issue 3/2004

Login to get access

Abstract

The size and complexity of the genomes of mammals in general, and humans in particular, is such that it will take many years to utilise this information to produce a genuine understanding of the control of cell behaviour. Since there are tens of thousands of genes to consider, the task of identifying those which play the most significant roles, biologically and medically, is both crucial and very demanding. Here we emphasise the importance of functional approaches to answering this question, i.e. the application of techniques which use the function of the gene itself in identifying the critical rate-limiting steps in biological processes. In this review, we use the functional analysis of one of the most important of these processes, the control of survival and apoptosis, to illustrate the power of a number of functional genomic strategies.
Literature
1.
Farzaneh F, Cooper D (eds) (1995) The human genome: a functional analysis. Bios Scientific Publishers, Oxford
2.
Stark GR, Gudkov AV (1999) Forward genetics in mammaliancells: functional approaches to gene discovery. Hum Mol Genet 8:1925CrossRefPubMed
3.
4.
Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456PubMed
5.
Hale AJ, Smith CA, Sutherland LC, Stoneman VEA., Longthorne VL, Culhane AC, Williams GT (1996) Apoptosis: molecular regulation of cell death. Eur J Biochem 236:1PubMed
6.
7.
Rathmell JC, Thompson CB (2002) Pathways of apoptosis in lymphocyte development, homeostasis and disease. Cell 109:S97PubMed
8.
Sutherland LC, Edwards SE, Cable HC, Poirier GG, Miller BA, Cooper CS, Williams GT (2000) LUCA-15-encoded sequence variants regulate CD95-mediated apoptosis. Oncogene 19:3774CrossRefPubMed
9.
Sutherland LC, Lerman M, Williams GT, Miller BA (2001) LUCA-15 suppresses CD95-mediated apoptosis in Jurkat T cells. Oncogene 20:2713.)CrossRefPubMed
10.
Mourtada-Maarabouni M, Sutherland LC, Williams GT (2002) Candidate tumour suppressor LUCA-15 can regulate multiple apoptotic pathways. Apoptosis 7:421–432CrossRefPubMed
11.
Mourtada-Maarabouni M, Sutherland LC, Meredith JM, Williams GT (2003) Simultaneous acceleration of the cell cycle and suppression of apoptosis by splice variant delta-6 of the candidate tumour suppressor LUCA-15/RBM5. Genes Cells 8:109–119CrossRefPubMed
12.
Williams GT, Smith CA (1993) Molecular regulation of apoptosis: genetic controls on cell death. Cell 74:777PubMed
13.
14.
McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB, Shirali S, Hediger MA, Farzaneh F, Simpson RJ (2001) Iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291:1755CrossRefPubMed
15.
McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ (2000) A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Molecular Cell 5:299PubMed
16.
Darling D, Hughes C, Galea-Lauri J, Gäken J, Trayner ID, Kuiper M, Farzaneh F (2000) Low speed centrifugation of retroviral vectors absorbed to a particulate substrate: a highly effective means of enhancing retroviral titre. Gene Therapy 7:914CrossRefPubMed
17.
Hughes C, Galea-Lauri J, Farzaneh F, Darling D (2001) Streptavidin MagneSphere paramagnetic particles: a choice of three affinity based capture and magnetic concentration strategies for retroviral vectors. Mol Ther 3:623CrossRefPubMed
18.
Starr R, Willson TA, Viney EM, Murray LJL, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917CrossRefPubMed
19.
Rayner JR, Gonda TJ (1994) A simple and efficient procedure for generating stable expression libraries by cDNA cloning in a retroviral vector. Mol Cell Biol 14:880PubMed
20.
Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, Francke U, Reed JC, Kinoshita S, Nolan GP (1998) Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity 8:461PubMed
21.
Sun P, Dong P, Dai K, Hannon GJ, Beach D (1998) P53-independent role of MDM 2 in TGF-β1 resistance. Science 282:2270CrossRefPubMed
22.
Hannon GJ, Sun P, Carnero A, Xie LY, Maestro R, Conklin DS, Beach D (1999) MaRX: an approach to genetics in mammalian cells. Science 283:1129CrossRefPubMed
23.
Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190:1375PubMed
24.
Maestro R, Tos APD, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13:2207CrossRefPubMed
25.
Carnero A, Hudson JD, Hannon GJ, Beach DH (2000) Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model. Nucleic Acids Res 28:2234CrossRefPubMed
26.
Legerski R, Peterson C (1992) Expression cloning of a human DNA-repair gene involved in Xeroderma-Pigmentosum group-C. Nature 359:70CrossRefPubMed
27.
Kimchi A (1998) DAP genes: novel apoptotic genes isolated by a functional approach to gene cloning. Biochim Biophys Acta 1377:F13CrossRefPubMed
28.
Inbal B, Cohen O, PolakCharcon S, Kopolovic J, Vadai E, Eisenbach L, Kimchi A (1997) DAP kinase links the control of apoptosis to metastasis. Nature 390:180CrossRefPubMed
29.
Mourtada-Maarabouni M, Kirkham L, Jenkins B, Rayner J, Gonda TJ, Starr R, Trayner I, Farzaneh F, Williams GT (2003) Functional expression cloning reveals pro-apoptotic role for protein phosphatase 4. Cell Death Differ 10:1016CrossRefPubMed
30.
31.
Putney LK, Denker SP, Barber DL (2002) The changing face of the Na+/H+ exchanger, NHE1: structure, regulation, and cellular actions. Annu Rev Pharmacol Toxicol 42:52CrossRef
32.
Grosovsky AJ, Skandalis A, Hasegawa L, Walter BN (1993) Insertional inactivation of the tk locus in a human B lymphoblastoid cell line by a retroviral shuttle vector. Mutat Res Fundam Mol Mech Mutagen 289:297CrossRef
33.
Levy LS, Lobelle-Rich PA, Overbaugh J (1993) Flvi-2, a target of retroviral insertional mutagenesis in feline thymic lymkphosarcomas, encodes bmi-1. Oncogene 8:1833PubMed
34.
35.
Gaiano N, Amsterdam A, Kawakami K, Allende M, Becker T, Hopkins N (1996) Insertional mutagenesis and rapid cloning of essential genes in zebrafish. Nature 383:829CrossRefPubMed
36.
Lu SJ, Man S, Bani MR, Adachi D, Hawley RG, Kerbel RS, Ben-David Y (1995) Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum(II) resistance. Cancer Res 55:1139PubMed
37.
Just U, Boettiger D, Kan O, Dexter TM, Spooncer E (2000) Insertional mutagenesis as a route to identifying genes involved in self renewal of haemopoietic stem cells. Curr Top Microbiol Immunol 251:27PubMed
38.
Li J et al (1999) Leukaemia disease genes: large-scale cloning & pathway predictions. Nat Genet 23:348–353PubMed
39.
Lund AH et al (2002) Genome-wide retroviral insert tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 32:160–165CrossRefPubMed
40.
Mikkers H, Allen J, Knipscheer P, Romeyn L, Hart A, Vink E, Berns A (2002) High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 32:153–159CrossRefPubMed
41.
Suzuki T et al (2002) New genes involved in cancer identified by retroviral tagging. Nat Genet 32:166–174CrossRefPubMed
Metadata
Title
The use of gene function to identify the rate-limiting steps controlling cell fate
Authors
Gwyn T. Williams
Farzin Farzaneh
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0476-6

Other articles of this Issue 3/2004

Cancer Immunology, Immunotherapy 3/2004 Go to the issue

Review

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors

Review

Dendritic cell biology and cancer therapy

Review

Natural killer lymphocytes: biology, development, and function

Review

Tetraspanins connect several types of Ig proteins: IgM is a novel component of the tetraspanin web on B-lymphoid cells

Review

Immunological inhibition of carcinogenesis

Review

Tumour escape: antitumour effectors too much of a good thing?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits